Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2003 1
2004 15
2005 49
2006 49
2007 57
2008 52
2009 40
2010 44
2011 55
2012 36
2013 70
2014 47
2015 59
2016 60
2017 74
2018 57
2019 34
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

696 results
Results by year
Filters applied: . Clear all
Page 1
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Goetz MP, et al. J Clin Oncol 2017 - Clinical Trial. PMID 28968163
Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in 493 postmenopausal women with HR-positive, HER2-negative advanced breast cancer who had no prior systemic therapy in the advanced setting. ...Conclusion Abemaciclib plus a nonsteroidal aromatase inhibitor was effective as initial therapy, significantly improving progression-free survival and objective response rate and demonstrating a tolerable safety profile in women with HR-positive, HER2-negative advanced breast cancer....
Methods MONARCH 3 is a double-blind, randomized phase III study of abemaciclib or placebo plus a nonsteroidal aromatase inhibitor in …
Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis.
Goldvaser H, et al. J Natl Cancer Inst 2018 - Review. PMID 28922781
BACKGROUND: A number of randomized controlled trials (RCTs) have reported improvement in breast cancer outcomes from extending treatment with aromatase inhibitors (AIs) beyond the initial five years after diagnosis. ...
BACKGROUND: A number of randomized controlled trials (RCTs) have reported improvement in breast cancer outcomes from extending treatment wit …
Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Chlebowski RT, et al. Cancer 2015. PMID 25757699 Free PMC article.
Although aromatase inhibitors reduce breast cancer incidence, their influence on endometrial cancer is uncertain. METHODS: The authors investigated this issue in a cohort of 17,064 women who were diagnosed with hormone receptor-positive breast cancer in an integrated group practice health plan. ...In addition, aromatase inhibitors may mitigate the incidence of tamoxifen-associated endometrial cancer. Although there were somewhat fewer endometrial cancers in the aromatase inhibitor group versus the no endocrine therapy group, further studies are needed for the definitive assessment of this potential association....
Although aromatase inhibitors reduce breast cancer incidence, their influence on endometrial cancer is uncertain. METHODS: The …
Hormone Therapy in Breast Cancer
Drăgănescu M and Carmocan C. Chirurgia (Bucur) 2017 - Review. PMID 28862117 Free article.
The aromatase inhibitors: Anastrozol, Letrozol, Exemestan are only used in postmenopause. Fulvestrant is used in recurrent disease after or during treatment with Tamoxifen. ...
The aromatase inhibitors: Anastrozol, Letrozol, Exemestan are only used in postmenopause. Fulvestrant is used in recurrent dis …
Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years.
Goss PE, et al. N Engl J Med 2016 - Clinical Trial. PMID 27264120 Free PMC article.
BACKGROUND: Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of choice for hormone-receptor-positive early breast cancer in postmenopausal women. ...CONCLUSIONS: The extension of treatment with an adjuvant aromatase inhibitor to 10 years resulted in significantly higher rates of disease-free survival and a lower incidence of contralateral breast cancer than those with placebo, but the rate of overall survival was not higher with the aromatase inhibitor than with placebo. ...
BACKGROUND: Treatment with an aromatase inhibitor for 5 years as up-front monotherapy or after tamoxifen therapy is the treatment of …
Managing side effects in adjuvant endocrine therapy for breast cancer
Condorelli R and Vaz-Luis I. Expert Rev Anticancer Ther 2018 - Review. PMID 30188738
Areas covered: This review examines the spectrum and consequences of adverse effects of tamoxifen and aromatase inhibitors, and the pharmacological and non-pharmacological approaches to mitigate some of the most frequent and disturbing side effects of endocrine therapy (including vasomotor, musculoskeletal, and vulvovaginal symptoms). ...
Areas covered: This review examines the spectrum and consequences of adverse effects of tamoxifen and aromatase inhibitors, an …
Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer.
Daldorff S, et al. Br J Cancer 2017 - Review. PMID 27923036 Free PMC article.
The nonsteroidal aromatase inhibitors anastrozole and letrozole, as well as the steroidal aromatase inactivator exemestane, are the preferred drugs and established worldwide in all clinical phases of the disease. ...Finally, we summarise some of the promising findings made with the combination of aromatase inhibitors with other potent endocrine treatment options like fulvestrant, a selective oestrogen receptor downregulator....
The nonsteroidal aromatase inhibitors anastrozole and letrozole, as well as the steroidal aromatase inactivator exemest …
Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review
Matthews A, et al. BMJ 2018. PMID 30297439 Free PMC article.
Results suggested an increased risk of venous thromboembolism in tamoxifen users compared with both non-users and aromatase inhibitor users. Results were also consistent with a higher risk of the vascular diseases myocardial infarction and angina in aromatase inhibitor users compared with tamoxifen users, but there was also a suggestion that this may be partly driven by a protective effect of tamoxifen on these outcomes. ...
Results suggested an increased risk of venous thromboembolism in tamoxifen users compared with both non-users and aromatase inhibitor …
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
De Placido S, et al. Lancet Oncol 2018 - Clinical Trial. PMID 29482983
BACKGROUND: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and, to our knowledge, no trial has directly compared the three aromatase inhibitors anastrozole, exemestane, and letrozole. ...INTERPRETATION: 5 years of treatment with aromatase inhibitors was not superior to 2 years of tamoxifen followed by 3 years of aromatase inhibitors. ...
BACKGROUND: Uncertainty exists about the optimal schedule of adjuvant treatment of breast cancer with aromatase inhibitors and …
696 results
Jump to page
Feedback